C-Reactive Protein (CRP) is a general marker for inflammation and infection, so it can be used as a very rough proxy for 
heart disease risk. A level above 2.4 mg/l has been associated with a doubled risk of a coronary event (source: wikipedia.org). Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, it hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment according to an article of NEJM Journals on November 2008.
According to the article. currently the treatment of myocardial infarction, stroke, and death from cardiovascular causes recommend statin therapy for patients with established vascular disease, diabetes, and hyperlipidemia. Many previous study shown that statin therapy reduces high-sensitivity C-reactive protein levels.
Paul M Ridker, M.D. and his colleagues for the JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) Study Group investigated whether treatment with rosuvastatin, 20 mg daily, would decrease the rate of first major cardiovascular events.
The trial’s (JUPITER) outcome was the occurrence of a first major cardiovascular event defined as nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, an arterial revascularization procedure, or confirmed death from cardiovascular causes and its component considered individually such arterial revascularization or hospitalization for unstable angina, myocardial infarction, stroke, or death from cardiovascular causes — and death from any cause.
Find the complete result ot this trial about Does Statin Regiment (Rosuvastatin) associated with reducing high CRP Levels? here in PDF Filetype provided. See also another Heart Article you may browse.
